Test Price
2,800 AED✅ Home Collection Available
CYP2C9 Gene Warfarin Resistance Genetic Test in Dubai – Pharmacogenomic NGS Analysis
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity via ISO 9001:2015 certified processing (Certificate: INT/EGQ/2509DA/3139).
- VIP Phlebotomy Logistics: Temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM by DHA-licensed phlebotomists.
- Post-Test Clinical Counselling: Telehealth consultation with a DHA-licensed clinical geneticist to interpret the pharmacogenomic report and guide warfarin dose individualisation.
- Insurance Verification: Direct WhatsApp coverage check at +971 54 548 8731.
- DHA Facility License: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Test Overview & Methodology
This next-generation sequencing (NGS) pharmacogenomic assay analyses the complete coding region of the CYP2C9 gene to detect variants that alter sensitivity to coumarin anticoagulants (warfarin/acenocoumarol). The clinical report provides star-allele assignment (including *1, *2, *3, *5, *6, *8, *11, *13) and a predicted metaboliser phenotype (poor, intermediate, or normal) to enable precision warfarin dosing. Compared to legacy genotyping methods, NGS offers comprehensive variant coverage and reduces the risk of misclassification in patients of diverse ancestry.
| Feature | Our CYP2C9 NGS Test | Standard Genotyping (e.g., PCR-RFLP) |
|---|---|---|
| Technology | Next Generation Sequencing – full gene coverage including promoter and intronic regions | Limited-variant PCR or targeted microarrays |
| Variant Detection | All clinically relevant *1, *2, *3, *5, *6, *8, *11, *13 alleles plus rare/novel variants | Typically only *2 and *3; misses many resistance-associated alleles |
| Clinical Actionability | Star allele assignment + phenotype prediction (poor/intermediate/normal metaboliser) with supporting literature references | Phenotype may be misclassified; limited guidance for complex polypharmacy patients |
| Turnaround Time | 3 to 4 Weeks (comprehensive analysis and clinical report) | 1 to 5 Days (limited SNPs only) |
Physician Insight & Safety Protocols
“CYP2C9 pharmacogenomic testing provides critical guidance for warfarin initiation and maintenance dosing. However, the genotype is one component of a comprehensive clinical assessment that must include INR monitoring, dietary considerations, concomitant medications, and patient-specific factors such as age and comorbidities. This NGS assay is designed to reduce the risk of adverse drug events, not to replace medical judgment. Always interpret results in the context of the full clinical picture.”
Lina Osama Zaki Quteineh – Consultant Medical Genetics | DHA Registration ID: 9294403
Critical Medication Advisory
Do not discontinue prescribed warfarin or any anticoagulant without explicit consultation with your treating physician. Abrupt cessation may precipitate life-threatening thromboembolic events. This genetic test supports dose individualisation; it does not replace clinical monitoring, INR management, or emergency intervention for bleeding complications.
Patient Safety – Exclusion Criteria & Red Flags
- Exclusion: Individuals unable to provide informed consent for genetic testing; patients with recent blood transfusion or allogeneic transplant (may interfere with germline DNA analysis); minors without parental or guardian consent as per Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Red Flags (Seek emergency care immediately): Severe haemorrhage, uncontrolled bleeding, spontaneous bruising, haematemesis, melena, or signs of warfarin-induced skin necrosis.
- This test cannot replace emergency INR management; if you experience any unexplained bleeding, go to the nearest emergency department without delay.
Patient FAQ & Clinical Guidance
1. What exactly does this CYP2C9 NGS test detect and why is it important for warfarin therapy?
This NGS test detects genetic variants in the CYP2C9 gene that influence how your body metabolises warfarin and other coumarin anticoagulants. By sequencing the entire gene, it identifies both common star alleles (*1, *2, *3, *5, *6, *8, *11, *13) and rare mutations that can cause warfarin resistance or increased sensitivity. The report provides a predicted metaboliser phenotype — poor, intermediate, or normal — helping your physician select a safer starting dose and reducing the risk of bleeding complications or therapeutic failure. This test is recommended before initiating warfarin therapy or when a patient demonstrates unexplained resistance to standard dosing.
2. How should I prepare for the test and what sample type is required?
Preparation involves a mandatory pre-test genetic counselling session conducted via telehealth, during which a family pedigree is documented. No fasting or medication changes are required unless your physician specifically advises otherwise. The test requires a standard venous blood sample, which can be collected at home through our VIP phlebotomy service operating daily from 8 AM to 11 PM. All samples are transported under strict temperature-controlled cold-chain conditions to ensure DNA integrity. Alternative sample types such as extracted DNA or FTA card blood spots can be accepted upon prior arrangement.
3. How will my doctor use the test results in clinical practice and is warfarin still safe to take?
Your doctor will integrate your CYP2C9 genotype with clinical factors such as age, weight, diet, kidney function, and concurrent medications to optimise your warfarin dose. For example, individuals carrying CYP2C9*2 or *3 variants typically require lower doses, while certain rare variants may indicate resistance requiring higher doses or alternative anticoagulation strategies. Warfarin remains a highly effective and safe anticoagulant when monitored with regular INR testing; genotyping simply adds a layer of precision to reduce the time needed to achieve a stable therapeutic INR. This test does not replace routine blood monitoring but significantly enhances dose individualisation and safety.
4. What is the turnaround time for results and how will I receive my report?
The standard turnaround time is 3 to 4 weeks from sample collection. This duration allows for comprehensive sequencing, bioinformatic analysis, clinical interpretation by our Consultant Medical Geneticist, and preparation of a detailed pharmacogenomic report. Results are delivered electronically through our secure patient portal and are accompanied by a telehealth follow-up consultation with our genetics team to explain the findings and answer any questions. Urgent requests can be expedited in certain clinical scenarios — please contact our patient coordination team for details.
5. Does my health insurance cover the cost of this genetic test?
Insurance coverage for pharmacogenomic testing varies by insurer and policy. We offer a direct WhatsApp verification service at +971 54 548 8731 where our team will check your coverage eligibility before the test is performed. For self-paying patients, the total cost is 2,800 AED, which includes genetic counselling, sample collection, comprehensive NGS analysis, and the post-test clinical consultation. Payment can be made by card, bank transfer, or through our secure online payment gateway.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
- Licensed by Dubai Health Authority under Facility License Number 1143
- Full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient genetic data
- Adherence to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for digital health data management
- Clinical testing safety and patient consent governed by Federal Decree-Law No. 4 of 2016 on Medical Liability
- ISO 9001:2015 Certified – Certificate Number INT/EGQ/2509DA/3139
- All genetic data encrypted and stored on UAE-based secure servers; no data is transferred outside the jurisdiction without explicit patient consent
- Pre-test genetic counselling and informed consent obtained in accordance with DHA standards for genetic testing
Clinical & Logistical Metadata
| Test Name | CYP2C9 Gene Warfarin Resistance Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21 to 28 Working Days (3 to 4 Weeks) |
| Sample Type / Matrix | Peripheral Whole Blood (3–5 mL in EDTA tube); alternative: extracted genomic DNA (2 µg minimum) or FTA card blood spot |
| Methodology Used | Next Generation Sequencing (Illumina platform) – full gene coverage including coding regions, UTRs, and exon-intron boundaries |
| ICD-10-CM Code | Z13.71 – Encounter for genetic testing for prothrombotic state; Z13.858 – Encounter for other specified genetic testing (pharmacogenomic) |
| LOINC Code | 74525-7 – CYP2C9 gene mutations found in Blood or Tissue by Molecular genetics method |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians